An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
2. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
3. The ECOG score was 0 or 1.
4. Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
5. Adequate bone marrow and organ function.

1. Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
2. Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
3. Participants with active, known or suspected autoimmune diseases.
4. Other malignant tumors within 5 years before screening.
5. Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
6. Participants with severe cardiovascular and cerebrovascular diseases.
7. There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
8. Arterial and venous thrombosis events occurred within 3 months before the first administration.
9. HIV test positive.
10. Participants with active hepatitis B or C.

1.Evidence of active tuberculosis infection within 1 year before the first administration.

12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.

14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.